Liver Cancer Diagnostics Market Report 2025

The liver cancer diagnostics market size has grown strongly in recent years. It will grow from $9.69 billion in 2024 to $10.4 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to biopsy techniques and histopathology, development of biomarker detection, evolution of screening programs, advances in genetic testing, improvements in liver imaging modalities.

The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $13.86 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to regulatory changes and standardization, growing importance of imaging modalities, development of next-generation sequencing, expanded screening programs and awareness, rising demand for biomarker-based testing. Major trends in the forecast period include rise in incidence and prevalence, advancements in imaging technologies, focus on non-invasive diagnostics, precision medicine and personalized diagnostics, integration of artificial intelligence (AI).

The anticipated rise in the prevalence of liver cancer is set to drive the growth of the liver cancer diagnostics market. Liver cancer, characterized by the uncontrolled growth of liver cells, poses a severe health risk. Diagnostic tests for liver cancer play a crucial role in determining the extent of cancer cell spread within or around the liver following the diagnosis of primary liver carcinoma. A report from the American Cancer Society revealed an increase in new cases of liver and intrahepatic bile duct cancer among females, reaching 13,230 in 2023 in the United States. The total estimated new cases of liver cancer for 2023 in the US are 41,210, with an expected 29,380 fatalities. This underscores the pressing need for liver cancer diagnostics due to the escalating prevalence of the disease.

The growing prevalence of hepatitis B is anticipated to further boost the liver cancer diagnostics market. Hepatitis B, a viral infection affecting the liver, can lead to both acute and chronic conditions. Regular monitoring is essential for individuals with chronic hepatitis B to assess liver health and detect signs of liver damage or cancer. According to the Centers for Disease Control and Prevention, approximately 296 million people, including over 6 million children under the age of 5, are affected by hepatitis B. This growing prevalence of hepatitis B is a significant driver for the expansion of the liver cancer diagnostics market.

Key companies in the liver cancer diagnostics market are creating advanced biomarker-based assays and algorithms to enhance diagnostic accuracy and facilitate early detection. Biomarker-based assays and algorithms are diagnostic tools that employ specific biological markers to identify diseases, offering more precise and efficient diagnostic capabilities. For example, in November 2023, Roche Diagnostics, a U.S.-based biotech corporation, introduced the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm. The Elecsys PIVKA-II assay identifies elevated levels of the PIVKA-II biomarker, which is linked to hepatocellular carcinoma (HCC), thereby improving early liver cancer detection in high-risk patients. Meanwhile, the Elecsys GAAD algorithm combines various diagnostic markers, including PIVKA-II and AFP, to enhance diagnostic accuracy and streamline decision-making in liver cancer detection.

In April 2023, Integrated DNA Technologies, a U.S.-based biotechnology company, acquired Archer NGS research assays for an undisclosed sum. This acquisition was intended to strengthen Integrated DNA Technologies' portfolio in next-generation sequencing (NGS), with a focus on expanding its research capabilities and enhancing assay development for genomic research. Archer, Inc. is recognized as a U.S. provider of diagnostic solutions for liver cancer.

In December 2022, Fujifilm Holdings Corporation acquired Inspirata, an oncology informatics and healthcare IT solutions provider, for an undisclosed amount. The acquisition included Dynamyx digital pathology technology and involved the integration of Inspirata's staff and clients into Fujifilm. This strategic move allows Fujifilm to expand its Synapse Enterprise Imaging portfolio, incorporating pathology data and images into electronic medical record systems to streamline cancer patient treatment and support care teams.

Major companies operating in the liver cancer diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp.

North America was the largest region in the liver cancer diagnostics market in 2024. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liver cancer diagnostics encompass a range of techniques utilized for the identification and assessment of liver cancer, a malignancy originating in the liver. These methods play a crucial role in the early detection and diagnosis of liver cancer, utilizing both imaging and molecular testing.

Hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other related forms constitute the primary types of cancer addressed in liver cancer diagnostics. Hepatocellular carcinoma (HCC) specifically pertains to the predominant liver cancer affecting individuals with cirrhosis and preexisting chronic liver disease. The screening process involves various approaches such as laboratory testing, imaging, endoscopy, biopsy, and others. Diverse technologies, including fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), among others, are employed across different end uses, including hospitals and diagnostic laboratories, academic and research institutes, and pharmaceutical and CRO laboratories.

The liver cancer diagnostics market research report is one of a series of new reports that provides liver cancer diagnostics market statistics, including liver cancer diagnostics industry global market size, regional shares, competitors with a liver cancer diagnostics market share, detailed liver cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer diagnostics industry. This liver cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver cancer diagnostics market includes revenues earned by entities by liver transplants, CT scans, and liver function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer diagnostics market also includes sales of In Vitro and Imaging Tools, AI tools, and ML tools which are used in providing liver cancer diagnostic services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.